#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neonatal alloimmune thrombocytopenia Immune-mediated myasthenia gravis Anti-glomerular basement membrane disease Craniopharyngioma Parkinson's disease Myxoid liposarcoma Dermatitis Neuroendocrine carcinoma Acute respiratory distress syndrome Superficial vein thrombosis Vaginal cancer Niemann-Pick disease Non-small cell lung cancer metastatic Rheumatoid arthritis Pulmonary alveolar haemorrhage More trials…

    Learn about Rare Diseases

    Krabbe’s disease – Trials in Disease Mantle cell lymphoma – Life with Disease Familial amyotrophic lateral sclerosis – Diagnostics Nodal marginal zone B-cell lymphoma – Treatment Von Willebrand’s disease Atypical teratoid/rhabdoid tumour of CNS – Treatment Gaucher’s disease type I – Basic Information Biotinidase deficiency – Treatment Turner’s syndrome – Life with Disease Congenital generalised lipodystrophy – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Kan-101 ZUNIBERGENE ROCPARVOVEC Rmc-6291 Polatuzumab Vedotin Futibatinib Azd5863 Tigecycline Rbp030.2 Panitumumab Cloxacillin Arachis Hypogaea Extract Avacopan RUBIDIUM CHLORIDE Micafungin Alendronic Acid Fosamprenavir Calcium Niflumic Acid R2R01 Tildacerfont Rilpivirine More therapies…

    Learn about Your Condition

    Bladder cancer stage III Idiopathic pulmonary fibrosis Lip and/or oral cavity cancer Metastatic malignant melanoma Pyelonephritis Procedural haemorrhage Mitral valve incompetence Alveolar rhabdomyosarcoma Osteoporosis Gingival bleeding Hypertriglyceridaemia Breast cancer male Diabetic autonomic neuropathy Cervix carcinoma stage IV Myopia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fondation A De Rothschild

Fondation A De Rothschild

29 Rue Manin, Paris, 75019, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Corticosteroids and Rituximab to Prevent Worsening of Ocular Myasthenia Gravis in Newly Diagnosed Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Dexchlorpheniramine Maleate
    • Methylprednisolone Hemisuccinate
    • Azathioprine
    France

  • Study on the Safety and Effectiveness of Lufepirsen Gel for Patients with Persistent Corneal Epithelial Defects

    Recruiting

    2 1
    Investigated Diseases:
    • Persistent corneal epithelial defect
    Investigated Drugs:
    • Lufepirsen
    France Germany Italy Spain

  • Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

    Recruiting

    3 1 1
    Investigated Diseases:
    • Progressive relapsing multiple sclerosis
    • Relapsing multiple sclerosis
    • Secondary progressive multiple sclerosis
    Investigated Drugs:
    • Anhydrous Cholestyramine
    • Magnetic Resonance Imaging Contrast Media
    • Teriflunomide
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

    Recruiting

    3 1
    Investigated Diseases:
    • Myasthenia gravis
    Investigated Drugs:
    • Iptacopan
    Denmark France Germany Greece Italy The Netherlands +3

  • Study of dimethyl fumarate to slow the progression of geographic atrophy in patients with age-related macular degeneration (dry form)

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Macular degeneration
    Investigated Drugs:
    • Dimethyl Fumarate
    France

  • Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azetukalner
    Austria Belgium Bulgaria Croatia Czechia Finland +10

  • Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Uveitis
    Investigated Drugs:
    • Fluorescein Sodium
    • Isoniazid
    • Rifampicin
    France

  • Study on Azathioprine for Preventing Relapse in Patients with Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOG-AD) After First Attack

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azathioprine
    • Hydrocortisone
    • Prednisolone
    France

  • Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

    Recruiting

    3 1
    Investigated Drugs:
    • Azetukalner
    Austria Belgium Bulgaria Croatia Czechia Finland +8

  • Study on the Safety and Effects of UX701 Gene Therapy for Adults with Wilson Disease

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Adeno-Associated Viral Vector Serotype 9 Encoding Human Atp7B
    • Eculizumab
    • Tacrolimus
    Denmark France Germany Italy Portugal Spain
Previous Page
1 2 3 4 5 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!